Serotonin Transporter Binding Potentials in Brain of Juvenile Monkeys 1 Year After Discontinuation of a 2-Year Treatment With Fluoxetine

Overview

Journal Biol Psychiatry Cogn Neurosci Neuroimaging

Specialties Neurology
Psychiatry
Radiology

Date 2019 Sep 1

PMID 31471184

Citations 3

Authors

Mari S Golub

Casey E Hogrefe

Lillian J Campos

Andrew S Fox

Affiliations

Soon will be listed here.

Abstract

Background: The potential long-term effects of childhood fluoxetine therapy on brain serotonin systems were studied using a nonhuman primate model, the rhesus monkey.

Methods: Juvenile male rhesus (1-4 years of age, corresponding to 4-11 years of age in children) were treated orally with fluoxetine (2 mg/kg) or vehicle daily for 2 years and removed from treatment during the third year. Each treatment group was assigned an equal number of subjects with low and high transcription polymorphisms of MAOA. One year after discontinuation of treatment, positron emission tomography scans were conducted (n = 8 treated monkeys, n = 8 control monkeys) using [C]DASB to quantify serotonin transporter in 16 cortical and subcortical regions.

Results: Fluoxetine-treated monkeys with MAOA low transcription polymorphism had significantly lower [C]DASB binding potentials than control monkeys. This finding was seen throughout the brain but was strongest in prefrontal and cingulate cortices. The MAOA × fluoxetine interaction was enhanced by binding potentials that were nonsignificantly higher in monkeys with high transcription polymorphism.

Conclusions: Juvenile fluoxetine treatment has residual posttreatment effects on brain serotonin transporter that depend on MAOA genotype. MAOA genotype may be important to consider when treating children with fluoxetine.

Citing Articles

Delineation of biomarkers and molecular pathways of residual effects of fluoxetine treatment in juvenile rhesus monkeys by proteomic profiling.

Yan Y, Park D, Horn A, Golub M, Turck C Zool Res. 2022; 44(1):30-42.

PMID: 36266933 PMC: 9841182. DOI: 10.24272/j.issn.2095-8137.2022.196.

Long-Term Fluoxetine Administration Causes Substantial Lipidome Alteration of the Juvenile Macaque Brain.

Tkachev A, Stekolshchikova E, Bobrovskiy D, Anikanov N, Ogurtsova P, Park D Int J Mol Sci. 2021; 22(15).

PMID: 34360852 PMC: 8348031. DOI: 10.3390/ijms22158089.

Combining brain perturbation and neuroimaging in non-human primates.

Klink P, Aubry J, Ferrera V, Fox A, Froudist-Walsh S, Jarraya B Neuroimage. 2021; 235:118017.

PMID: 33794355 PMC: 11178240. DOI: 10.1016/j.neuroimage.2021.118017.

References

Goertzen A, Bao Q, Bergeron M, Blankemeyer E, Blinder S, Canadas M . NEMA NU 4-2008 comparison of preclinical PET imaging systems. J Nucl Med. 2012; 53(8):1300-9. PMC: 4128012. DOI: 10.2967/jnumed.111.099382. View

Karere G, Sullivan E, Kinnally E, Capitanio J, Lyons L . Enhancing genotyping of MAOA-LPR and 5-HTT-LPR in rhesus macaques (Macaca mulatta). J Med Primatol. 2012; 41(6):407-11. PMC: 3492537. DOI: 10.1111/jmp.12024. View

Brummelte S, Mc Glanaghy E, Bonnin A, Oberlander T . Developmental changes in serotonin signaling: Implications for early brain function, behavior and adaptation. Neuroscience. 2016; 342:212-231. PMC: 5310545. DOI: 10.1016/j.neuroscience.2016.02.037. View

Christian B, Fox A, Oler J, Vandehey N, Murali D, Rogers J . Serotonin transporter binding and genotype in the nonhuman primate brain using [C-11]DASB PET. Neuroimage. 2009; 47(4):1230-6. PMC: 2798593. DOI: 10.1016/j.neuroimage.2009.05.090. View

Hutchison S, Masse L, Pawluski J, Oberlander T . Perinatal selective serotonin reuptake inhibitor (SSRI) effects on body weight at birth and beyond: A review of animal and human studies. Reprod Toxicol. 2018; 77:109-121. DOI: 10.1016/j.reprotox.2018.02.004. View

Klomp A, Tremoleda J, Wylezinska M, Nederveen A, Feenstra M, Gsell W . Lasting effects of chronic fluoxetine treatment on the late developing rat brain: age-dependent changes in the serotonergic neurotransmitter system assessed by pharmacological MRI. Neuroimage. 2011; 59(1):218-26. DOI: 10.1016/j.neuroimage.2011.07.082. View

Button K, Ioannidis J, Mokrysz C, Nosek B, Flint J, Robinson E . Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013; 14(5):365-76. DOI: 10.1038/nrn3475. View

Kalbitzer J, Frokjaer V, Erritzoe D, Svarer C, Cumming P, Nielsen F . The personality trait openness is related to cerebral 5-HTT levels. Neuroimage. 2009; 45(2):280-5. DOI: 10.1016/j.neuroimage.2008.12.001. View

Olivier J, Blom T, Arentsen T, Homberg J . The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: A review. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 35(6):1400-8. DOI: 10.1016/j.pnpbp.2010.09.013. View

10.

Chang C, Chen M, Lu J . Effect of antidepressant drugs on the vmPFC-limbic circuitry. Neuropharmacology. 2015; 92:116-24. PMC: 4346479. DOI: 10.1016/j.neuropharm.2015.01.010. View

11.

Ichise M, Vines D, Gura T, Anderson G, Suomi S, Higley J . Effects of early life stress on [11C]DASB positron emission tomography imaging of serotonin transporters in adolescent peer- and mother-reared rhesus monkeys. J Neurosci. 2006; 26(17):4638-43. PMC: 6674071. DOI: 10.1523/JNEUROSCI.5199-05.2006. View

12.

Golub M, Hogrefe C, Bulleri A . Regulation of emotional response in juvenile monkeys treated with fluoxetine: MAOA interactions. Eur Neuropsychopharmacol. 2016; 26(12):1920-1929. PMC: 5154301. DOI: 10.1016/j.euroneuro.2016.10.010. View

13.

Su S, Hogrefe-Phi C, Asara J, Turck C, Golub M . Peripheral fibroblast metabolic pathway alterations in juvenile rhesus monkeys undergoing long-term fluoxetine administration. Eur Neuropsychopharmacol. 2016; 26(7):1110-8. PMC: 5590669. DOI: 10.1016/j.euroneuro.2016.03.017. View

14.

Yu Y, Tsai S, Hong C, Chen T, Chen M, Yang C . Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology. 2005; 30(9):1719-23. DOI: 10.1038/sj.npp.1300785. View

15.

Wegerer V, Moll G, Bagli M, Rothenberger A, Ruther E, Huether G . Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life. J Child Adolesc Psychopharmacol. 1999; 9(1):13-24; discussion 25-6. DOI: 10.1089/cap.1999.9.13. View

16.

Levitt P, Pintar J, Breakefield X . Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci U S A. 1982; 79(20):6385-9. PMC: 347126. DOI: 10.1073/pnas.79.20.6385. View

17.

Tai C, Chatziioannou A, Siegel S, Young J, Newport D, Goble R . Performance evaluation of the microPET P4: a PET system dedicated to animal imaging. Phys Med Biol. 2001; 46(7):1845-62. DOI: 10.1088/0031-9155/46/7/308. View

18.

Wilson A, Ginovart N, Schmidt M, Meyer J, Threlkeld P, Houle S . Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines. J Med Chem. 2000; 43(16):3103-10. DOI: 10.1021/jm000079i. View

19.

Kinnally E, Tarara E, Mason W, Mendoza S, Abel K, Lyons L . Serotonin transporter expression is predicted by early life stress and is associated with disinhibited behavior in infant rhesus macaques. Genes Brain Behav. 2009; 9(1):45-52. PMC: 2823956. DOI: 10.1111/j.1601-183X.2009.00533.x. View

20.

Norgaard M, Ganz M, Svarer C, Frokjaer V, Greve D, Strother S . Optimization of preprocessing strategies in Positron Emission Tomography (PET) neuroimaging: A [C]DASB PET study. Neuroimage. 2019; 199:466-479. PMC: 6688914. DOI: 10.1016/j.neuroimage.2019.05.055. View